FDA Approves Bristol-Myers Squibb's Onglyza
Onglyza is an oral prescription medicine used along with diet and exercise to control high blood sugar in adults with type 2 diabetes.
Onglyza works by enhancing the body's natural ability to control high blood sugar. It can be used alone or together with one of several common oral diabetes medicines, such as metformin, a thiazolidinedione (TZD), or a sulfonylurea.
Onglyza (saxagliptin) is an oral diabetes medicine that helps control blood sugar levels. It works by regulating the levels of insulin your body produces after eating.
Onglyza is for people with type 2 diabetes (non-insulin-dependent) diabetes. Saxagliptin is sometimes used in combination with other diabetes medications, but is not for treating type 1 diabetes.
The FDA today approved Onglyza, a once-daily treatment for type 2 diabetes to be taken in combination with diet and exercise.
Onglyza, made by Bristol-Myers Squibb and distributed by Bristol-Myers Squibb and AstraZeneca Pharmaceuticals, was tested in diabetes patients at relatively low risk of heart disease. The FDA approval requires Bristol-Myers Squibb to conduct a postmarketing study to evaluate the drug's heart safety in higher-risk patients.
Onglyza is a prescription medicine licensed for the treatment of type 2 diabetes. It has several effects on the body, including increasing insulin production in response to meals and decreasing the amount of glucose that the liver produces. The medication comes in tablet form and is usually taken once daily. This product is only approved for use in adults.